Real-World ARON-3 Data Highlight the Advantage of Triplet Therapy in High-Volume mHSPC
At the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, pivotal real-world data from the international ARON-3 study were revealed, advancing treatment insights for high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastases. The ARON-3 study evaluated 841 patients receiving either doublet therapy, combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors […]